Trilogy Capital »

Crispr Therapeutics shares owned by Trilogy Capital

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Trilogy Capital from 13F filings

Historical chart of Trilogy Capital investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Trilogy Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Trilogy Capital

Quarter filed Position value Share count Share price at filing
2024-09-30 $230k 4.9k 46.98
2024-06-30 $265k 4.9k 54.01

More positions owned by Trilogy Capital

Invesco Qqq Tr Unit Ser 1 (QQQ)
Invesco Exchange Traded Fd T S&p500 Quality (SPHQ)
Vanguard Bd Index Fds Total Bnd Mrkt (BND)
Ishares Tr Msci Usa Qlt Fct (QUAL)
Ishares Tr Msci Usa Mmentm (MTUM)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Spdr Ser Tr Portfolio Agrgte (SPAB)
Spdr Ser Tr Bloomberg 1-3 Mo (BIL)
Invesco Exchange Traded Fd T S&p Mdcp Quality (XMHQ)
First Tr Value Line Divid In SHS (FVD)
Vanguard Index Fds Total Stk Mkt (VTI)
Wisdomtree Tr Intl Qulty Div (IQDG)
Thor Finl Technologies Tr Low Volatility (THLV)
Schwab Strategic Tr Fundamental Us S (FNDA)
Wisdomtree Tr Yield Enhancd Us (AGGY)

View all positions for Trilogy Capital

Top funds holding Crispr Therapeutics

Capital Research and Management Company - Division 3
ARK Investment Management
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
BlackRock
BlackRock
T. Rowe Price Investment Management
State Street Corporation
Vanguard Group
NEA Management Company
Citadel Advisors
EcoR1 Capital
Susquehanna International
Bank of America Corporation
Sr One Capital Management

View all funds holding Crispr Therapeutics